176 related articles for article (PubMed ID: 28903331)
1. The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status.
Mohammed F; Stones DH; Zarling AL; Willcox CR; Shabanowitz J; Cummings KL; Hunt DF; Cobbold M; Engelhard VH; Willcox BE
Oncotarget; 2017 Aug; 8(33):54160-54172. PubMed ID: 28903331
[TBL] [Abstract][Full Text] [Related]
2. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775115
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self.
Mohammed F; Cobbold M; Zarling AL; Salim M; Barrett-Wilt GA; Shabanowitz J; Hunt DF; Engelhard VH; Willcox BE
Nat Immunol; 2008 Nov; 9(11):1236-43. PubMed ID: 18836451
[TBL] [Abstract][Full Text] [Related]
4. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.
Molvi Z; Klatt MG; Dao T; Urraca J; Scheinberg DA; O'Reilly RJ
bioRxiv; 2023 Feb; ():. PubMed ID: 36798179
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.
Andersen MH; Bonfill JE; Neisig A; Arsequell G; Sondergaard I; Valencia G; Neefjes J; Zeuthen J; Elliott T; Haurum JS
J Immunol; 1999 Oct; 163(7):3812-8. PubMed ID: 10490979
[TBL] [Abstract][Full Text] [Related]
6. Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1.
Magarian-Blander J; Ciborowski P; Hsia S; Watkins SC; Finn OJ
J Immunol; 1998 Apr; 160(7):3111-20. PubMed ID: 9531265
[TBL] [Abstract][Full Text] [Related]
7. Endogenous presentation of a nascent antigenic epitope to CD8+ CTL is more efficient than exogenous presentation.
Hahn YS; Hahn CS; Braciale TJ
Immunol Cell Biol; 1996 Oct; 74(5):394-400. PubMed ID: 8912001
[TBL] [Abstract][Full Text] [Related]
8. Analysis of peptide binding patterns in different major histocompatibility complex/T cell receptor complexes using pigeon cytochrome c-specific T cell hybridomas. Evidence that a single peptide binds major histocompatibility complex in different conformations.
Bhayani H; Paterson Y
J Exp Med; 1989 Nov; 170(5):1609-25. PubMed ID: 2553848
[TBL] [Abstract][Full Text] [Related]
9. Structural analysis of two HLA-DR-presented autoantigenic epitopes: crucial role of peripheral but not central peptide residues for T-cell receptor recognition.
De Oliveira DB; Harfouch-Hammoud E; Otto H; Papandreou NA; Stern LJ; Cohen H; Boehm BO; Bach J; Caillat-Zucman S; Walk T; Jung G; Eliopoulos E; Papadopoulos GK; van Endert PM
Mol Immunol; 2000 Oct; 37(14):813-25. PubMed ID: 11257303
[TBL] [Abstract][Full Text] [Related]
10. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
12. A TCR mimic monoclonal antibody reactive with the "public" phospho-neoantigen pIRS2/HLA-A*02:01 complex.
Dao T; Mun SS; Molvi Z; Korontsvit T; Klatt MG; Khan AG; Nyakatura EK; Pohl MA; White TE; Balderes PJ; Lorenz IC; O'Reilly RJ; Scheinberg DA
JCI Insight; 2022 Mar; 7(5):. PubMed ID: 35260532
[TBL] [Abstract][Full Text] [Related]
13. Non-canonical anchor motif peptides bound to MHC class I induce cellular responses.
Lazoura E; Lodding J; Farrugia W; Day S; Ramsland PA; Apostolopoulos V
Mol Immunol; 2009 Mar; 46(6):1171-8. PubMed ID: 19118903
[TBL] [Abstract][Full Text] [Related]
14. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.
Zarling AL; Polefrone JM; Evans AM; Mikesh LM; Shabanowitz J; Lewis ST; Engelhard VH; Hunt DF
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14889-94. PubMed ID: 17001009
[TBL] [Abstract][Full Text] [Related]
15. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.
Carson RT; Vignali KM; Woodland DL; Vignali DA
Immunity; 1997 Sep; 7(3):387-99. PubMed ID: 9324359
[TBL] [Abstract][Full Text] [Related]
16. Non-canonical peptides bound to MHC.
Day SL; Ramsland PA; Apostolopoulos V
Curr Pharm Des; 2009; 15(28):3274-82. PubMed ID: 19860676
[TBL] [Abstract][Full Text] [Related]
17. T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen.
Ehrich EW; Devaux B; Rock EP; Jorgensen JL; Davis MM; Chien YH
J Exp Med; 1993 Aug; 178(2):713-22. PubMed ID: 8393480
[TBL] [Abstract][Full Text] [Related]
18. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
Denkberg G; Klechevsky E; Reiter Y
J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
[TBL] [Abstract][Full Text] [Related]
19. On the molecular nature of "restrictive" antigenic elements present on major histocompatibility complex (MHC) proteins.
Novotny J; Bruccoleri RE; Kourilsky P
Res Immunol; 1989 Feb; 140(2):145-58. PubMed ID: 2472656
[TBL] [Abstract][Full Text] [Related]
20. Immunobiological analysis of TCR single-chain transgenic mice reveals new possibilities for interaction between CDR3alpha and an antigenic peptide bound to MHC class I.
Zhang W; Honda S; Wang F; DiLorenzo TP; Kalergis AM; Ostrov DA; Nathenson SG
J Immunol; 2001 Oct; 167(8):4396-404. PubMed ID: 11591764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
